Lyra Therapeutics (LYRA) Accumulated Depreciation & Amortization (2019 - 2025)
Quarterly Accumulated Depreciation & Amortization rose 10.17% to $4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Dec 2025, up 10.17% year-over-year, with the annual reading at $4.5 million for FY2025, 10.17% up from the prior year.
Lyra Therapeutics' Accumulated Depreciation & Amortization history spans 7 years, with the latest figure at $4.5 million for Q4 2025.
- Accumulated Depreciation & Amortization came in at $4.5 million for Q4 2025, up from $4.4 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $4.7 million in Q3 2022 to a low of $1.9 million in Q4 2023.
- The 5-year median for Accumulated Depreciation & Amortization is $4.1 million (2022), against an average of $3.9 million.
- Year-over-year, Accumulated Depreciation & Amortization tumbled 53.98% in 2023 and then skyrocketed 114.94% in 2024.
- Lyra Therapeutics' Accumulated Depreciation & Amortization stood at $3.9 million in 2021, then rose by 7.61% to $4.2 million in 2022, then crashed by 53.98% to $1.9 million in 2023, then surged by 114.94% to $4.1 million in 2024, then rose by 10.17% to $4.5 million in 2025.
- Per Business Quant, the three most recent readings for LYRA's Accumulated Depreciation & Amortization are $4.5 million (Q4 2025), $4.4 million (Q3 2025), and $4.3 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Lyra Therapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.55 Mn |
| Dec 31, 2025 | 4.55 Mn |
| Sep 30, 2025 | 4.45 Mn |
| Sep 30, 2025 | 4.45 Mn |
| Jun 30, 2025 | 4.35 Mn |
| Jun 30, 2025 | 4.35 Mn |
| Mar 31, 2025 | 4.26 Mn |
| Mar 31, 2025 | 4.26 Mn |
| Dec 31, 2024 | 4.13 Mn |
| Dec 31, 2024 | 4.13 Mn |
| Sep 30, 2024 | 4.12 Mn |
| Sep 30, 2024 | 4.12 Mn |
| Jun 30, 2024 | 4.08 Mn |
| Jun 30, 2024 | 4.08 Mn |
| Dec 31, 2023 | 1.92 Mn |
| Dec 31, 2023 | 1.92 Mn |
| Dec 31, 2022 | 4.17 Mn |
| Dec 31, 2022 | 4.17 Mn |
| Sep 30, 2022 | 4.72 Mn |
| Sep 30, 2022 | 4.72 Mn |
| Jun 30, 2022 | 4.45 Mn |
| Jun 30, 2022 | 4.45 Mn |
| Mar 31, 2022 | 4.16 Mn |
| Mar 31, 2022 | 4.16 Mn |
| Dec 31, 2021 | 3.88 Mn |
| Dec 31, 2021 | 3.88 Mn |
| Sep 30, 2021 | 3.60 Mn |
| Sep 30, 2021 | 3.60 Mn |
| Jun 30, 2021 | 3.25 Mn |
| Jun 30, 2021 | 3.25 Mn |
| Mar 31, 2021 | 2.95 Mn |
| Mar 31, 2021 | 2.95 Mn |
| Dec 31, 2020 | 2.88 Mn |
| Dec 31, 2020 | 2.88 Mn |
| Sep 30, 2020 | 2.84 Mn |
| Sep 30, 2020 | 2.84 Mn |
| Jun 30, 2020 | 2.85 Mn |
| Jun 30, 2020 | 2.85 Mn |
| Mar 31, 2020 | 2.84 Mn |
| Mar 31, 2020 | 2.84 Mn |
| Dec 31, 2019 | 2.83 Mn |
| Dec 31, 2019 | 2.83 Mn |